Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | Healthcare Professional Site | XPOVIO® |
Description | The first and only FDA‑approved XPO1 inhibitor that helps restore the body’s own tumor suppressor XPOVIO treats adult patients with multiple myeloma who have received at least 1 prior therapy or with relapsed/refractory disease. See Full Safety |
Keywords | N/A |
WebSite | xpoviopro.com |
Host IP | 38.87.43.142 |
Location | United States |
Site | Rank |
US$10,916,526
Last updated: 2023-05-08 17:47:01
xpoviopro.com has Semrush global rank of 969,567. xpoviopro.com has an estimated worth of US$ 10,916,526, based on its estimated Ads revenue. xpoviopro.com receives approximately 1,259,600 unique visitors each day. Its web server is located in United States, with IP address 38.87.43.142. According to SiteAdvisor, xpoviopro.com is safe to visit. |
Purchase/Sale Value | US$10,916,526 |
Daily Ads Revenue | US$10,077 |
Monthly Ads Revenue | US$302,304 |
Yearly Ads Revenue | US$3,627,646 |
Daily Unique Visitors | 83,974 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
xpoviopro.com. | A | 3599 | IP: 38.87.43.142 |
xpoviopro.com. | NS | 3600 | NS Record: ns43.domaincontrol.com. |
xpoviopro.com. | NS | 3600 | NS Record: ns44.domaincontrol.com. |
xpoviopro.com. | TXT | 3600 | TXT Record: google-site-verification=OPzF1n9QHTjDQxrwgQiFqbr_xqPkpoJ839NHLUPMkxU |
This site is intended for US healthcare professionals only. Important Safety Information Prescribing Information Patient Website Indications Multiple Myeloma (MM) Relapsed or Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) Multiple Myeloma MM Relapsed or Refractory Diffuse Large B-Cell Lymphoma RR DLBCL The first and only FDA‑approved XPO1 inhibitor that helps restore the body’s own tumor suppressor pathways. 1-3 The X Factor Restore Your Patients Own Cancer Defenses Restore your patients’ own cancer defenses In MM or RR DLBCL, INDICATIONS XPOVIO ® (selinexor) is a prescription medicine approved: in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma (MM) who have received at least one prior therapy. IMPORTANT SAFETY INFORMATION Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in |
HTTP/1.1 200 OK Cache-Control: private,max-age=600 Content-Length: 47328 Content-Type: text/html Last-Modified: Tue, 05 Oct 2021 17:08:19 GMT Accept-Ranges: bytes ETag: "80823798bbad71:0" Server: Microsoft-IIS/10.0 X-Powered-By: ASP.NET Content-Security-Policy: default-src 'self' https: data: 'unsafe-inline' 'unsafe-eval' Referrer-Policy: no-referrer-when-downgrade Strict-Transport-Security: max-age=31536000; includeSubdomains X-Content-Type-Options: nosniff X-Frame-Options: SAMEORIGIN X-Xss-Protection: 1; mode=block Date: Sat, 30 Oct 2021 11:19:30 GMT |
Domain Name: XPOVIOPRO.COM Registry Domain ID: 2449216298_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2019-10-29T17:28:42Z Creation Date: 2019-10-29T17:28:41Z Registry Expiry Date: 2021-10-29T17:28:41Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS43.DOMAINCONTROL.COM Name Server: NS44.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-17T21:41:00Z <<< |